摘要
目的:观察依达拉奉治疗急性脑梗死的临床疗效。方法:80例急性脑梗死患者随机分为治疗组40例和对照组40例,对照组使用常规的应用抗血小板凝集、改善微循环和对症等治疗,治疗组在对照组的基础上加用依达拉奉注射液30mg+0.9%氯化钠注射液100ml,静脉滴注,每天2次,共用14天。治疗前后定期对患者进行欧洲卒中评分(ESS)及日常生活能力(ADL)的评定。结果:各组治疗后10天ESS及ADL评分差异有显著性,治疗组在两方面均优于对照组(P<0.05),14天后治疗组在显效率及有效率方面明显高于对照组(P<0.05);且无明显不良反应。结论:依达拉奉治疗急性脑梗死安全、有效。
Objective：To observe the clinical efficacy of edaravone treatment of acutecerebral infarction.Methods：80 cases of acute cerebral infarction were randomly divided into 40 cases,40 cases of the treatment group and control group,control groupusing the conventional application of anti-platelet aggregation,microcirculation,and symptomatic treatment,treatment group on the basis of the control group according to edaravone injection 30mg ＋0.9% Sodium Chloride Injection 100ml,intravenous infusion 2 times a day,sharing 14 days.Before and after treatment for patients on aregular basis,the European stroke scale （ESS）,and daily living （ADL） were assessed.Results：Treatment in each group after 10 days ESS and ADL score difference was significant,the treatment group than the control group （P 0.05） in both areas,14 days after thetreatment group was significantly higher in the effective rate and efficiency （P 0.05）;and no significant adverse reactions.Conclusions：in accordance with the safety ofedaravone in the treatment of acute cerebral infarction.
出处
《中国伤残医学》
2012年第6期17-18,共2页
Chinese Journal of Trauma and Disability Medicine
关键词
急性脑梗死
依达拉奉
疗效观察
Acute cerebral infarction
Edaravone
Efficacy observed
